SYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spyre Therapeutics Inc (SYRE) is not an immediate buy for a beginner investor with a long-term focus. While the company has potential in its pipeline and analysts are optimistic, the lack of strong technical signals, weak financial performance, and absence of recent positive catalysts suggest holding off on investment for now.
The stock shows mixed technical signals. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and contracting (-0.344), and RSI is neutral at 56.392. The stock is trading near a pivot level of 40.777, with resistance at 42.522 and support at 39.031. Short-term stock trend analysis predicts minor fluctuations with a 70% chance of -0.57% next day and -5.58% next month.
Analysts from Mizuho and Citi have initiated coverage with optimistic ratings and price targets of $53 and $64, respectively. The company's pipeline for monoclonal antibodies and autoimmune treatments is seen as promising, with projected sales of $1.7B by 2035.
No significant news or trading trends from hedge funds, insiders, or Congress. Financial performance is weak, with negative net income (-$62.53M) and declining EPS (-18.63% YoY). The company has no revenue yet, and gross margin remains at 0%.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $62.53M (improved 11.07% YoY), and a decline in EPS to -0.83 (-18.63% YoY). Gross margin remains at 0%.
Mizuho and Citi have initiated coverage with 'Outperform' and 'Buy' ratings, citing the company's innovative pipeline and long-term sales potential. Price targets are set at $53 and $64, indicating upside potential.
